Summary by Moomoo AI
Medtronic reported Q1 FY25 revenue of $7.9 billion, increasing 2.8% as reported and 5.3% organic. GAAP diluted EPS rose 36% to $0.80, while non-GAAP diluted EPS grew 3% to $1.23. Growth was driven by strong performance across multiple franchises, including Cardiac Ablation Solutions, Neuromodulation, Spine, Structural Heart, and Diabetes.The Cardiovascular Portfolio led growth with 6.9% organic increase, followed by Neuroscience at 5.3% and Diabetes at 12.6%. Notable product innovations included the PulseSelect pulsed field ablation system, Evolut FX+ TAVR system, and MiniMed 780G automated insulin delivery system. The U.S. Diabetes segment showed particular strength with mid-teens growth.Based on strong Q1 performance, Medtronic raised its FY25 guidance, projecting organic revenue growth of 4.5-5% (up from 4-5%) and non-GAAP diluted EPS of $5.42-$5.50 (previously $5.40-$5.50). The company expects sustained growth from new product introductions while continuing strategic investments to support launches.
